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Abstract
Chronic obstructive pulmonary disease is a highly prevalent, underdiagnosed, and undertreated
chronic lung disease. Early and appropriate treatment may help modify the course of the disease with
respect to exacerbation timing and frequency, quality of life, and mortality. Steady progress continues
to be made in understanding the disease pathogenesis and treatment modalities, and there is some
evidence that outcomes are improving.
Introduction and context
Chronic obstructive pulmonary disease (COPD) is a
chronic progressive systemic inflammatory disease that is
generally a response to noxious particles and gases (most
often, tobacco smoke) in susceptible individuals,
although second-hand smoke, aging, other pollutants,
and HIV may also be associated with COPD. This disease
is expected to be the third leading cause of mortality
worldwide by 2020 [1]. It causes 2.7 million deaths
worldwide per year [2,3] and is associated with up to a
twofold-higher risk of cardiovascular mortality [4-6].
Classically, COPD is a heterogeneous condition
characterized by incompletely reversible airflow
obstruction, including emphysema, chronic bronchitis,
and bronchial hyperreactivity, often in combination.
Phenotypes of COPD may be further classified on the
basis of radiographic findings (i.e, the presence or absence
of emphysema and/or bronchial wall thickening) or
genetic polymorphisms. The main pathways studied in
association with COPD development are the inflamma-
tory,protease-antiprotease,andantioxidantpathways,but
unfortunately many studies looking at genetic poly-
morphisms either have shown no association with
COPD or had conflicting results, possibly related to the
choice of study population [7,8].
In 2001, the Global Initiative for Chronic Obstructive
Lung Disease (GOLD) was formed to improve the
investigation and management of this complex disease,
and treatment strategies have been recommended on the
basis of GOLD staging (Figure 1) [9]. Patients with
respiratory symptoms but no airflow obstruction are also
at increased risk for respiratory and cardiovascular
morbidity and mortality [10]. Recent research has
focused on identifying and modifying comorbidities
associated with COPD and therapies to improve the
significant individual and global morbidity and mortality
associated with this disease.
Spirometry provides the single best method of diagnosing
and staging COPD. The severity of COPD is staged
according to the forced expiratory volume in 1 second
(FEV1), which is the most reproducible parameter of
spirometric testing and the most significant predictor of
prognosis in COPD [11,12]. In healthy individuals, FEV1
declines by 20-30 mL per year, but this decline is
accelerated in patients with COPD [13]. Pharmacologic
therapiesforCOPDhavebeenassessedbymeasuringlung
function decline, number and timing of exacerbations,
and effect on mortality counterbalanced by the side effect
profile. Exacerbation endpoints have been of particular
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increased risk of myocardial infarction and stroke [14],
declineinlungfunction[15],declineinqualityoflife,and
an overall 14-18% 1-year mortality [16].
Recent advances
Pharmacologic agents
Long-acting antimuscarinic agents
Anticholinergic agents in COPD may be beneficial
because of the increased vagal tone in the airways of
patients with COPD [17]. Tiotropium is a once-daily,
inhaled anticholinergic therapy that was recently exam-
ined in the 4-year UPLIFT (Understanding Potential
Long-Term Impacts on Function with Tiotropium) trial
[18]. In this study, patients were at least 40 years of age
(mean age 64.5), 90% had GOLD stage 2 or 3 COPD,
and more than 60% were already on long-acting beta-
agonists (LABAs) or inhaled corticosteroids (ICSs)
(or both). Tiotropium was not shown to significantly
reduce the rate of decline in FEV1 but was associated with
improvements in quality of life, reduced time to first
exacerbation (16.7 versus 12.5 months), delayed time to
first hospitalization for an exacerbation, and a reduced
mean number of exacerbations by 14% (P <0.001)
during the 4-year period [18].
Long-acting bronchodilator and inhaled corticosteroids
The addition of a long-acting bronchodilator is recom-
mended for patients with moderate (FEV1/forced vital
capacity ratio of <70%, FEV1 of <80%) or worse COPD
based on GOLD staging, and ICSs are recommended for
patients with an FEV1 of less than 50% or with frequent
exacerbations. Studies examining the effects of ICSs
alone have not shown any effecton lung function decline
over time and have had conflicting results in regard to
exacerbation rate reduction [19-21].
Current LABA-ICS combinations are marketed under the
trade names Advair (salmeterol/fluticasone propionate;
GlaxoSmithKline, Uxbridge, Middlesex, UK) and Symbi-
cort (formoterol/budesonide; AstraZeneca, London,
UK). The TORCH (Towards a Revolution in COPD
Health) trial examined the effects of salmeterol and
fluticasone propionate on survival in COPD over the
course of 3 years [10]. A non-statistically significant trend
in improved survival was observed in patients receiving
the LABA-ICS combination compared with placebo (P =
0.052) or either of the individual components. The
LABA-ICS combination group did have a reduced annual
rate of exacerbations (1.13 to 0.85) and improved health
status according to the St George’s Respiratory Ques-
tionnaire [10]. A post hoc analysis found that treatment
with salmeterol-fluticasone propionate reduced the rate
of decline in FEV1 in patients with moderate to severe
COPD – a finding that has not been demonstrated with
other pharmacologic therapies [22].
‘Triple’ combination therapy
In one study, 660 patients with moderate, severe, or
very severe COPD (mean FEV1 1.1 L) were randomly
assigned to receive tiotropium plus placebo and
tiotropium plus budesonide/formoterol over the course
of 12 weeks. Patients on triple-combination therapy
showed statistically significant improvement in their
pre-dose and post-dose FEV1, capacity of daily living
questionnaire, and COPD symptoms. Furthermore, the
number of severe exacerbations was reduced by 62%
(rate ratio 0.38, 95% confidence interval [CI] 0.25-0.57,
P <0.001) [23].
In the OPTIMAL (Optimal Therapy of Chronic Obstruc-
tive Pulmonary Disease To Prevent Exacerbations and
Improve Quality of Life) study looking at tiotropium in
combination with salmeterol-fluticasone, lung function
and quality of life were also shown to improve compared
with tiotropium plus placebo or salmeterol alone over
the course of 1 year. However, in this study, mortality
and the proportion of patients who experienced an
exacerbation did not differ between the groups, although
the number of hospitalizations required because of an
exacerbation was reduced in patients on tiotropium plus
salmeterol-fluticasone (rate ratio 0.53, 95% CI 0.33-
0.86) [24].
Figure 1. Chronic obstructive pulmonary disease (COPD) stages
and treatment recommendations from the guidelines of the
Global Initiative on Obstructive Lung Disease [9]
1 Same as 1
ADD regular 
treatment with a 
bronchodilator
ADD 
rehabilitation
Same as 2
ADD inhaled 
steroids if 
repeated 
exacerbations
Same as 3
ADD long term 
oxygen if 
hypoxemic
Consider surgical 
interventions
COPD Stages
1 (FEV1 >80%)* 2 (FEV1 50-80%) 3 (FEV1 30-50%) 4 (FEV1 <30% )
Risk factor 
reduction
Influenza 
vaccination
Symptomatic 
treatment with 
short acting agent
*In all categories, FEV1/FVC is less than 70% of predicted following administration of an
inhaled bronchodilator
FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity.
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Other pharmacologic treatments for COPD have targeted
the inflammatory process and cardiovascular comorbid-
ity. Chronic low-dose macrolide therapy has been shown
to reduce exacerbation frequency and shorten duration
of exacerbations, although the antibacterial and anti-
inflammatory mechanisms remain unclear [25]. Roflu-
milast is an oral phosphodiesterase-4 inhibitor that
showed improvements in lung function (39-mL increase
in post-bronchodilator FEV1 compared with placebo,
P = 0.001) and exacerbation frequency (0.86 versus 0.92
exacerbations/patient per year for roflumilast versus
placebo) after 1 year of use in patients with severe
COPD [26]. Roflumilast is currently under study in
Europe, but the US Food and Drug Administration
recently rejected the application for drug approval in the
US because of concerns over possible adverse events such
as the possibility that neuropsychiatric reactions would
offset the ‘modest’ increase in lung function.
Mucolytics with anti-inflammatory and antioxidant
activity such as carbocisteine have also been shown to
reduce exacerbations in patients with moderate or worse
COPD [27]. The 3-hydroxy 3-methylglutaryl coenzyme A
reductase inhibitors (statins) may reduce the number of
COPD exacerbations and mortality from COPD, pre-
sumably via anti-inflammatory mechanisms, although
most previous studies do have inherent methodological
limitations[28,29].Likewise,treatmentwithbeta-blockers
may reduce the risk of exacerbations and improve survival
in patients with COPD, possibly as a result of cardiopul-
monary protective properties [30]. Exacerbation number
and severity may also be reduced with treatment with
non-typeable Haemophilus influenzae oral immunothera-
peuticHI-164OV [31]. Vitamin D replacement is currently
the subject of a placebo-controlled double-blinded
randomized controlled trial [32].
Side effects of treatment
The use of ICSs causes some concern over the risk for
osteoporosis and pneumonia. In the TORCH trial,
osteoporosis was highly prevalent in patients with
COPD (18% of men and 30% of women at baseline),
but the use of ICSs had no significant effect on bone
mineral density compared with placebo [33]. In contrast,
a meta-analysis of 18 randomized controlled trials
looking at the risk of pneumonia with long-term use
(at least 24 weeks) of ICSs in COPD did find a significant
increased risk of pneumonia (relative risk 1.60, 95% CI
1.33-1.92,P<0.001)butwithoutasignificantlyincreased
risk of pneumonia-related mortality or overall mortality
[34]. Analysis of the TORCH study also found a greater
risk of pneumonia in patients on ICSs alone or in
combination compared with placebo (84 and 88 versus
52 per 1000 treatment-years, respectively) [35]. The
definition of pneumonia (i.e., whether radiologic con-
firmation is required) may alter these findings. A meta-
analysis looking at fatal and non-fatal cardiovascular
events in patients treated with tiotropium found that
tiotropium did not significantly increase the risk of
adverse major cardiovascular events among patients with
COPD [36].
Other management modalities
Because it ameliorates decline in lung function, smoking
cessation remains the most important management issue
in COPD patients who continue to smoke. Other
considerations in the management of COPD include
assessing the need for chronic oxygen therapy given that
oxygen has been shown to improve mortality in patients
with chronic respiratory failure [37]; referral for pul-
monary rehabilitation, which improves quality of life
[38] and exacerbation severity [39]; and the use of non-
invasive ventilation, which improves quality of life with
variable effects on survival [40,41]. Importantly,
increased physical activity at home also translates into
a substantially reduced risk of readmission due to a
COPD exacerbation. Patients who walk at least 60
minutes a day had a statistically significant reduction
in risk of hospital readmission by almost 50%, and this
association did not change when adjusted for COPD
severity, nutritional status factors, or respiratory rehabi-
litation [42]. A recent study has suggested that abnormal
coordination of swallowing may lead to prandial
aspiration and trigger COPD exacerbations [43,44].
Referrals for lung volume reduction surgery and lung
transplant must also be considered for patients with
COPD. Lung volume reduction surgery should be
considered, especially for patients with both predomi-
nately upper-lobe emphysema and low-baseline exercise
capacity, as this surgery offers a survival benefit,
improved quality of life, and reduction in exacerbations.
In contrast, patients with non-upper lobe emphysema
and high-baseline exercise capacity are poor candidates
and have a higher mortality than patients treated with
medical therapy alone [45].
Outcomes
Recent data from the US suggest that COPD hospitaliza-
tion rates are no longer increasing and that COPD
mortality rates are starting to decrease [46,47]. These
findings are encouraging and may be a result of
improved diagnosis and better treatment.
Implications for clinical practice
COPD is now recognized as a systemic illness. Evidence
supports the use of inhaled pharmacotherapy to improve
Page 3 of 5
(page number not for citation purposes)
F1000 Medicine Reports 2010, 2:72 http://f1000.com/reports/medicine/content/2/72lung function, quality of life, and exacerbation frequency
and severity in patients with severe and very severe
disease and in many patients with moderate disease.
Until recently, only smoking cessation was found to
reduce the decline in FEV1, but there are now some data
that show that pharmacotherapy may also be effective
[48]. Furthermore, early intervention may have effects
that are more dramatic and decrease the time to first
exacerbation [49]. Maintenance therapy for moderate to
severe COPD with long-acting antimuscarinics and
LABA-ICS combinations appears to provide benefits in
health status, exacerbation rates, and probably mortality.
We continue to recognize the important role that
exacerbations play in the course of COPD, and therapy
directed toward reducing exacerbation rate and severity
will hopefully lead to further improvements in quality of
life, lung function, and mortality.
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